Headline News

 

RINVOQ shows continued repigmentation through 76 weeks in nonsegmental vitiligo

Posted on October 04, 2026

IMAAVY maintains disease control through two years in adolescents with generalised myasthenia gravis

Posted on October 04, 2026

ICOTYDE maintains skin clearance through two years in difficult to treat plaque psoriasis

Posted on October 04, 2026

FDA expands CAMZYOS approval to paediatric patients with obstructive hypertrophic cardiomyopathy

Posted on October 04, 2026

Foundayo linked to lower predicted long term diabetes and cardiovascular risk in ATTAIN 1 analysis

Posted on October 04, 2026

FDA expands Jaypirca approval to certain previously untreated CLL and SLL patients

Posted on October 04, 2026

AstraZeneca, Daiichi Sankyo and Summit to study Datroway plus ivonescimab across multiple cancers

Posted on October 04, 2026

LITFULO improves facial and total body repigmentation in Phase III vitiligo trials

Posted on October 04, 2026

Pfizer’s tilrekimig meets primary endpoint in Phase II atopic dermatitis study

Posted on October 04, 2026

Novo Nordisk secures exclusive global license from Hengrui Pharma for once-weekly oral GLP-1/GIP dual agonist HRS-1596

Posted on September 29, 2026

Lilly unveils Change the Course Commitment aimed at closing diabetes and obesity treatment gaps in lower-income countries

Posted on September 29, 2026

Lilly’s Foundayo at 17.2 mg outperforms 25 mg oral semaglutide on weight loss and A1C reduction, new indirect treatment comparison finds

Posted on September 29, 2026

Pfizer to showcase new cancer research spanning current standards of care and emerging pipeline breakthroughs at ESMO 2026

Posted on September 29, 2026

Alexion strengthens research leadership in gMG care with new data at 2026 AANEM Annual Meeting and MGFA Scientific Session

Posted on September 29, 2026

Perioperative Imfinzi combined with neoadjuvant enfortumab vedotin secures Priority Review status in the US for muscle-invasive bladder cancer patients

Posted on September 29, 2026